**Journal of Neonatal Surgery**
***ISSN(Online): 2226-0439***
***Vol. 14, Issue 7 (2025)***
*https://www.jneonatalsurg.com*

OPEN ACCESS

# AI-Assisted Design and Biochemical Optimization of Protein Structures for Enhanced Drug Delivery in Chemotherapy

**Kumaravel Kaliaperumal[1], Govindarajan S[2], Kamalam Ravi[3], Ian Pranandi[4], P Vinod Kumar[5], V M Gobinath[6]**

[1]Unit of Biomaterials research, Department of Orthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India,

Email ID: Kumarbio06@gmail.com

[2]Dept.of Civil Engineering, Aditya University., Surampalem, India,

ORCID id: 0000-0002-7682-321X

[3]Assistant professor of Biochemistry, Sree Balaji Medical College and Hospital, Chromepet, Chennai, 600044,

Email ID: kamalam11.apr@gmail.com,

ORCID id: 0000-0002-9625-3058

[4]Department of Biochemistry, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia,

Email ID: ian.pranandi@atmajaya.ac.id

[5]Professor Department of Forensic Medicine

Email ID: pv25kumar@gmail.com

[6]Department of Mechanical, Rajalakshmi Institute of Technology, Chennai,

Email ID : vmgobinath@gmail.com .

Cite this paper as: Kumaravel Kaliaperumal, Govindarajan S, Kamalam Ravi, Ian Pranandi, P Vinod Kumar, V M Gobinath,(2025) AI-Assisted Design and Biochemical Optimization of Protein Structures for Enhanced Drug Delivery in Chemotherapy. *Journal of Neonatal Surgery*, 14 (7), 147-151.

**ABSTRACT**

Chemotherapy remains the primary treatment for most malignancies; nevertheless, it is troubled by a handful of hindrances like non-specificity of the drug targeting agents, side effects, or actual drug resistance. Thus, protein engineering could be the answer to these problems by designing proteins capable of specific targeting of cancer cells, reducing unwanted drug toxicity, or carrying out controlled drug release. AI, in this regard, encompasses protein structure optimization for accelerated drug delivery and enhancement of the therapeutic efficacy. The present paper looks at AI utilization in protein engineering for drug delivery systems and its influence on chemotherapy, together with the possibility of using these innovations to combat existing challenges and enhance patient outcome**.**

***Keywords:*** *AI, Biochemical Optimization, Protein Structures, Drug Delivery, Chemotherapy, Cancer treatment.*

## INTRODUCTION

Chemotherapy remains one of the main forms of treating cancer; however, the process of drug delivery itself faces some of the most severe hurdles. Most of the classical chemotherapy agents affect the tumorous as well as the healthy tissues, and thus lead to horrible side effects such as immunosuppression, alopecia, and organ toxicity, which in turn diminishes the effectiveness of therapy and the quality of life of patients. In most cases, many tumors develop resistance to treatment within some time, which complicates the prognosis. This warrants a very urgent solution, such as protein engineering, to counter that challenge. By designing specialized proteins that will only target cancer cells with the highest specificity, enhancing drug solubility, and facilitating controlled release, protein-based delivery systems will make chemotherapy more precise and safer. Such engineered proteins-natural or manmade-will make way for a better and more biocompatible carrier of drugs.

## UNDERSTANDING CHEMOTHERAPY AND ITS CHALLENGES

Chemotherapy represents a mainstay of cancer treatment often in conjunction with surgery or radiation treatment. That refers

Artificial intelligence has rapidly emerged as a critical component in the advancement of protein engineering. In applying machine learning and predictive modeling, AI makes it possible to further hasten the identification and optimization processes to deliver precise and appropriate protein structures for drug delivery systems. Thus, this paper surveys how AI-assisted protein engineering technology can transcend the limitations of chemotherapy in improving its outcomes and reducing side effects. The scope of this paper includes examining the chemotherapy challenges, biochemical principles in optimizing proteins, the interface of AI technologies, and the future of drug delivery systems in cancer therapy

to the use of cytotoxic substances that act to kill rapidly dividing cancer cells. Yet for all its popularity, chemotherapy carries itself important shortcomings concerning lack of specificity (Yao and Wang, 2025). Traditional chemotherapeutic mechanisms travel widely around the body, causing collateral damage to rapidly dividing cells, including normal and healthy cells like epithelial cells lining the gastrointestinal tract, cells in the bone marrow, or hair follicles. Such untargeted nature produces adverse effects such as immunosuppression, nausea, alopecia, and increased chances of infections, greatly diminishing patient quality of life and, in rare cases, obstructing dose schedule and the time of treatments (Tyagi et al., 2025).

Another important hurdle confronting the present-day oncologists is tumor resistance. Tumors by nature are genetically unstable, thus making a rapid emergence of drug-resistant cancer cells possible. Mechanisms like enhanced drug efflux, DNA repair, and activation of alternative survival pathways promote resistance and reduce the therapeutic efficacy of standard chemotherapies; thereby, they worsen the overall prognosis of the patient (Serrano et al., 2024).

New and targeted drug delivery methods are becoming more important to meet these challenges. One of the new options that appear promising are protein-based delivery systems. Proteins can be designed to target specific cancer cell surface markers, allowing the conjugation of drugs to these proteins.

## BIOCHEMICAL PRINCIPLES OF PROTEIN ENGINEERING FOR DRUG DELIVERY

Proteins are complex macromolecules, which are chains of amino acids, folded into their three-dimensional structures. It is the structure including primary (amino acid sequence), secondary (α-helices and β-sheets), tertiary (the overall 3D folding), and quaternary (multi-subunit complexes) levels that determines the functional properties of proteins (Rajora et. al., 2020). Thus, drug delivery functions ideally because proteins have the ability to selectively attach to the target molecule, change their confirmation as per requirement, as well as remain stable in the biological environment. Simply because of their biocompatibility and biodegradability, they ensure that only a little amount of toxicity is produced while they can effectively clear themselves from their functions in the body (Qiu et al., 2024).

## ENGINEERING PROTEINS FOR DRUG DELIVERY

The aim of most designers in the new protein engineering is to achieve greater specificity and a high target for drug delivery. By modifying the binding domains, proteins could be developed to bind with their specific markers on the outer surface of a cancer cell, reducing damage to the other healthy tissues. An example of such engineering would be monoclonal antibodies such as trastuzumab that are directed specifically to the HER2 receptor that is sometimes overexpressed in certain breast cancers, allowing targeted drug delivery. (Moingeon et al., 2021).

Another important and pivotal factor is biocompatibility-the proteins would never elicit or induce any unwanted immune response, much less any toxicity. Engineering efforts were closely concentrated on this, either using already available human-origin proteins or modifying the already existing ones with the aim of reducing immunogenicity. Albumin, a naturally occurring protein in human plasma, is extremely biocompatible and has been successfully developed and used in drug delivery systems (Liang et al., 2020). A typical example was nab-paclitaxel, which improved the solubility of paclitaxel and its targeted delivery using albumin nanoparticles rather than the conventional formulation with less toxicity compared with that used in normal formulation.

## CONTROLLED RELEASE OF CHEMOTHERAPEUTIC AGENTS

Controlled drug delivery makes sure to send a therapeutic agent that is effective when needed and at the right place so that side effects can be minimized. The protein can be made to allow the drug to be released when specific changes are detected at the tumor site by low pH or high enzyme activity (Le et al., 2025). One example of that is engineered ferritin nanocages, which store chemotherapy drugs and release them in low pH areas in tumors. Another example is elastin-like polypeptides (ELPs), which become very responsive to changes in temperature in the body, accumulating at the tumor site and releasing the drug. Both natural and synthetically made proteins are utilized for drug delivery. For example, nab-paclitaxel, an albumin-based carrier, helps improve drug solubility and targeting (Gyanani et al., 2021). Engineered antibody-drug conjugates (ADCs) combine the highly specific targeting of antibodies with potent chemotherapeutic agents-for instance, ado-trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Furthermore, the platforms for precision chemotherapy

are being explored by developing alternative targeting and delivery platforms utilizing synthetic peptides and protein scaffolds, such as affibodies and DARPins (Bechelli and Delhommelle, 2024).

## ARTIFICIAL INTELLIGENCE IN PROTEIN DESIGN AND OPTIMIZATION

Advanced AI has changed biological research by studying large and complex data, finding hidden patterns, and predicting biological activities with extreme precision (Anand et al., 2022). In molecular biology- Genomics, Drug Discovery, Disease Modeling, Protein Design are important areas of artificial intelligence. Traditional methods such as X-ray Crystallography and NMR are slow and very expensive, though accurate (Amjad et al., 2023). AI tools provide such solutions faster and cheaper. Machine learning and deep learning design better proteins for drug delivery and treatments (Abbas et al., 2024).

## AI TECHNIQUES FOR PROTEIN STRUCTURE PREDICTION AND OPTIMIZATION

### MACHINE LEARNING MODELS (E.G., ALPHAFOLD)

AlphaFold is a state-of-the-art AI-based system by DeepMind that revolutionizes the prediction of protein structures. In the 2020 Critical Assessment of Structure Prediction (CASP14) competition, it performed exceedingly well, demonstrating its ability to predict shapes for proteins with very high accuracy, rivaling that of laboratory experiments (Yao and Wang, 2025). AlphaFold employs deep learning models trained on protein structures and sequence data that are publicly available, thus predicting a protein's 3D conformation from its amino acid sequence with high reliability.

The strength of AlphaFold lies in its innovative use of attention mechanisms to propagate contextual relationships of the amino acid residues at far away distances within the model (Tyagi et al., 2025). By establishing this barrier, the development allows structural biologists to rapidly model previously uncharacterized proteins, with a particular focus on those proteins involved in human disease and drug transport.

### NEURAL NETWORKS FOR SEQUENCE-TO-STRUCTURE MAPPING

Unsurprisingly, praises have been sung elsewhere. Other research programs focus on such neural network-based models for modeling the mapping of primary sequences to secondary and tertiary structures. RosettaFold and ProGen models take the step further into AI-assisted design of proteins with novel functionality. These models employ encoders and decoders, recurrent neural networks (RNNs), and transformer models to investigate the intricate correlation between amino acid sequence and the resultant folded structure.

In ProGen-a tool launched by Salesforce Research-protein sequences are treated like "sentences," and the model recognizes the "grammar" of operational proteins (Rosenkranz and Slastnikova, 2023). In this way, ProGen can create new functional protein sequences that do not naturally occur and thus create an exciting new avenue in proteomics, including the creation of special protein therapies, e.g. drug delivery systems for specific tumor conditions.

Artificial Intelligence has revolutionized protein design, by removing constraints of time that exist in conventional methodology. Within minutes or hours, the AI may predict a protein structure, but experimental work will take a few months or even years (Rasool et al., 2025). This ultimately saves costs by eliminating expensive equipment and chemicals. It helps investigate difficult targets that aren't available in the laboratory conditions and opens novel doors to drug discovery. AI can also model the structure of several proteins at the same time and thereby hastening research (Rajora et al., 2020). Finally, it can help synthesize entirely new protein designs, thus discovering things that natural evolution may not achieve.

## ENHANCED DRUG DELIVERY SYSTEMS USING AI-DESIGNED PROTEINS

Artificial intelligence engineered proteins harness targeted delivery of anticancer drugs and the concomitant lessened systemic toxicity. Chemotherapy associated toxicity is synonymous with off-target effects, as normal tissues are also damaged (Qiu et al., 2024). Such AI proteins are the most specific proteins that can bind and induce the receptors of cancer cells only and therefore lend to the accurate delivery of drugs. These tools make the delivery of drugs to tumor sites highly efficient while also significantly lowering any collateral damage of healthy cells.

AI-designed proteins also prevent systemic toxicity as they restrict the proteins from exposing the chemotherapeutic agents to no-target areas (Moingeon et al., 2021). Blood circulation time between delivery platforms and the corresponding tissues can be glued together to mold a therapeutically wider window for chemotherapy through much higher doses being possible to give in safety.

## INNOVATIONS IN PROTEIN NANOCARRIERS AND NANOPARTICLES

Hybrid protein nanocarriers that merge AI-engineered proteins with nanomaterials are a recent advancement (Liang et al., 2020). They make drugs more stable and allow controlled release, thereby ensuring that the chemotherapy drugs are only released when required. Moreover, they also enable the mixing of a variety of drugs for more effective cancer treatment using nanoparticles. Smart proteins that respond to the tumor environment are a novel concept with these systems (Le et al.,

2025). Such proteins may sense acidic or hypoxic conditions that are found mainly in tumors, releasing the drug only at the tumor site. This reduces side effects and improves treatment.

## APPLICATIONS IN SPECIFIC CANCER TREATMENTS

AI-designed proteins and protein nanocarriers have shown potential applications in treating cancers like breast cancer and lung cancer. For example, AI-designed peptides specifically targeting HER2 receptors were tested for breast cancer therapies to increase drug delivery accuracy (Gyanani et al., 2021). In a comparable manner, nanoparticle-based delivery systems targeting lung cancer cells are being evaluated for enhanced chemotherapeutic efficacy while reducing side effects.

## CHALLENGES AND ETHICAL CONSIDERATIONS

Notwithstanding the potential, AI-assisted protein engineering faces constraints. Among them is the limited availability of data since AI models operate on large datasets of high quality to be effective. Datasets lacking in variety would lead to poor designs or perhaps even erroneous designs for the said proteins and thus compromise the trustworthiness of the drug delivery systems (Bechelli and Delhommelle, 2024). Substantial computational resources are needed. High-performance computing is needed for protein design and optimization through AI, which could be additionally costly and time-consuming. These factors limit the scalability of AI-based approaches, particularly for smaller research labs or developing countries.

The application of AI gives rise to certain ethical challenges in biomedical research. First comes the issue of accountability; bias in AI models is yet another issue, with the understanding that algorithms may propagate biases inadvertently. This means that any treatment arising from such AI has an equal chance of being inequitable and entirely ineffective (Anand et al., 2022).

## FUTURE DIRECTIONS

Multi-functional protein designs have become one very exciting trend in AI-protein optimization. By targeting cancer cells and releasing chemotherapeutic agents in a controlled manner, proteins can perform multiple tasks simultaneously (Amjad et al., 2023). These multi-functional proteins would improve drug delivery systems significantly as they would increase the efficacy of drug delivery while reducing the side effects.

In tandem, there is also increasing interest in collaborative AI-human frameworks that will tap AI's advanced computing capabilities and enhance human knowledge of biological systems for more innovative, detailed analysis and ultimately even better results. AI can pair with human insight through data processing to create drug delivery systems that are more targeted and effective (Abbas et al., 2024).

Because AI-based protein optimization would enhance chemotherapy by making it more precise, reducing side effects and increasing efficacy, one can look forward to a revolution in cancer treatment-all other diseases will benefit from these technologies, which can be adapted to other diseases, such as autoimmune disorders or neurodegenerative conditions, offering new perspectives on targeted therapies in many areas of medicine (Yao and Wang, 2025).

## CONCLUSION

AI-based protein engineering is a breakthrough to overcome the limits imposed by classical chemotherapies. With enhanced specificity toward cancer cells, minimized systemic toxicity, and methods to counter drug resistance, protein-based delivery systems are thus expected to improve the effectiveness and safety of cancer therapy. The main added value is speeding up the design and optimization of these systems with AI in order to obtain even more personalized chemotherapy. Such innovations would probably transform cancer treatment as research progresses, improving the outcomes and quality of life of patients.

## REFERENCES

[1] Abbas, M. et al. (2024) ‘The Role of AI in Drug Discovery’, Chembiochem: A European Journal of Chemical Biology, 25(14), p. e202300816. Available at: https://doi.org/10.1002/cbic.202300816.

[2] Amjad, M.T., Kasi, A. and Chidharla, A. (2023) Cancer Chemotherapy, PubMed. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK564367/.

[3] Anand, U. et al. (2022) ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’, Genes & Diseases, 10(4), pp. 1367–1401. Available at: https://doi.org/10.1016/j.gendis.2022.02.007.

[4] Bechelli, S. and Delhommelle, J. (2024) ‘AI’s role in pharmaceuticals: Assisting drug design from protein interactions to drug development’, Artificial Intelligence Chemistry, 2(1), p. 100038. Available at: https://doi.org/10.1016/j.aichem.2023.100038.

[5] Gyanani, V., Haley, J.C. and Goswami, R. (2021) ‘Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems’, Pharmaceuticals, 14(9), p. 835. Available at:

https://doi.org/10.3390/ph14090835.

[6] Le, M.H.N. et al. (2025) 'An in-depth review of AI-powered advancements in cancer drug discovery', Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1871(3), p. 167680. Available at: https://doi.org/10.1016/j.bbadis.2025.167680.

[7] Liang, G. et al. (2020) 'The emerging roles of artificial intelligence in cancer drug development and precision therapy', Biomedicine & Pharmacotherapy, 128(110255), p. 110255. Available at: https://doi.org/10.1016/j.biopha.2020.110255.

[8] Moingeon, P., Kuenemann, M. and Guedj, M. (2021) 'Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine', Drug Discovery Today [Preprint]. Available at: https://doi.org/10.1016/j.drudis.2021.09.006.

[9] Qiu, X. et al. (2024) 'Advances in AI for Protein Structure Prediction: Implications for Cancer Drug Discovery and Development', Biomolecules, 14(3), p. 339. Available at: https://doi.org/10.3390/biom14030339.

[10] Rajora, A.K. et al. (2020) 'Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy', Pharmaceutics, 12(6), p. 592. Available at: https://doi.org/10.3390/pharmaceutics12060592.

[11] Rasool, A. et al. (2025) 'Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook', Frontiers in Oncology, 15. Available at: https://doi.org/10.3389/fonc.2025.1475893.

[12] Rosenkranz, A.A. and Slastnikova, T.A. (2023) 'Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells', Pharmaceutics, 15(3), pp. 987–987. Available at: https://doi.org/10.3390/pharmaceutics15030987.

[13] Serrano, D.R. et al. (2024) 'Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine', Pharmaceutics, 16(10), p. 1328. Available at: https://doi.org/10.3390/pharmaceutics16101328.

[14] Tyagi, E., Prakash, A. and Bhuyan, R. (2025) 'Cancer Ther Oncol Int J Enhancing Multi-Targeted Cancer Therapy with AI and Computational Drug Design', Cancer Ther Oncol Int J, 28(3). Available at: https://doi.org/10.19080/CTOIJ.2025.28.556239.

[15] Yao, J. and Wang, X. (2025) 'Artificial intelligence in de novo protein design', Medicine in Novel Technology and Devices, 26, p. 100366. Available at: https://doi.org/10.1016/j.medntd.2025.100366.